Erasca has reported updated preliminary Phase 1 data for its investigational pan-RAS molecular glue ERAS-0015, with encouraging responses in KRAS-mutant solid tumours and plans to advance the programme into potentially registration-enabling studies in pancreatic and lung cancer.

The updated findings come from the ongoing AURORAS-1 trial and include additional patients and longer follow-up than previously reported. The company also outlined plans to begin a potentially registration-enabling trial in second-line or later non-small cell lung cancer during the first half of 2027, followed by a Phase 3 pancreatic cancer trial in 2027 and a further Phase 3 lung cancer study between the second half of 2027 and the first half of 2028.

Among patients with second-line or later KRAS G12X pancreatic ductal adenocarcinoma treated with the recommended dose for expansion of 32 mg once daily, ERAS-0015 achieved an unconfirmed overall response rate of 57%, although the analysis was based on seven patients.

Across dose levels, patients with confirmed or unconfirmed responses remained on treatment at the data cut-off, with six of seven patients in the 32 mg cohort and six of eight patients in the 24 mg cohort continuing therapy.

The latest safety analysis remained consistent with previously reported findings. ERAS-0015 was generally well tolerated, with mostly low-grade treatment-related adverse events, no dose-limiting toxicities and no treatment discontinuations linked to adverse events. Median relative dose intensity remained 100% at both recommended dose levels.

Erasca also reported early combination data evaluating ERAS-0015 with panitumumab in metastatic colorectal cancer. No dose-limiting toxicities were observed in the first dose-escalation cohort receiving 16 mg ERAS-0015 alongside the approved dose of panitumumab, while dose escalation and enrolment continue.

Jonathan Lim, chairman, chief executive officer and co-founder of Erasca, said: “We believe the continued notable responses in patients with pancreatic cancer in the U.S., together with the encouraging data in lung cancer and early signal in combination with panitumumab in metastatic colorectal cancer that we have seen in Phase 1, underscore the broad potential of ERAS-0015 to become a foundational therapy for multiple RAS-mutant solid tumors.”

He added: “We look forward to additional preliminary monotherapy and combination data expected in the first half of 2027. We believe that we are well positioned to execute our robust clinical development plan and transition into Phase 3 development.”

ERAS-0015 is an investigational oral therapy designed to inhibit RAS signalling across multiple RAS mutations. Unlike mutation-specific inhibitors, pan-RAS therapies aim to target a broader range of cancers driven by abnormalities in the RAS signalling pathway, one of the most frequently altered pathways in cancer.

RAS mutations are found in a wide range of tumour types, including pancreatic, lung and colorectal cancers, making them an important focus for precision oncology research. The updated AURORAS-1 findings add to growing evidence supporting the potential of pan-RAS approaches, although larger studies will be needed to confirm the early efficacy and safety results observed in this Phase 1 programme.

If successful, the planned registration-enabling and Phase 3 studies could position ERAS-0015 as a potential new treatment option for patients with KRAS-mutant cancers, particularly in tumour types where effective therapies remain limited.